Depuy Spine Launches Next Generation Eagle And Swift Anterior Cervical Plating Systems
DePuy Spine, Inc. introduced its next generation in anterior Cervical fixation: the EAGLE™ Plus Rigid and the SWIFT™ Plus Dynamic Anterior Cervical Plating (ACP) Systems, which now offer more plating options for anatomically challenging procedures and incorporate new screw locking technology.
Correcting Spinal Deformities - DSM Dyneema And University Hospital Maastricht Collaborate To Explore New Solutions
DSM Dyneema and the university hospital Maastricht (azM), The Netherlands, announced a joint agreement to conduct research into new solutions that can improve surgical outcomes for patients with spinal deformities. Combining the materials technology of DSM Dyneema with the clinical expertise of the university, this project aims to develop new solutions that support the trend toward minimally invasive procedures as well as the need for preservation of mobility.
Mechanism Uncovered That Contribues To The Appropriate Formation Of The Spine
The Stowers Institute's Pourquie Lab has shed light on the mechanism causing animals to develop the appropriate number of vertebrae.Vertebrae are formed from their embryonic precursors, called somites. The number of somites is consistent within a species, but varies significantly across species.
By Using Growth Hormone Scientists From Granada Drastically Reduce The Wait Time For New Teeth Implant
The use of the growth hormone in oral implantology has managed to regenerate the bone and hasten the integration between the bone base and the dental implant. The process allows to reduce from six months to two weeks the wait time to place the crown which replaces the lost tooth on the oral implant.
Topical NSAID As Effective As Tablets For Knee Pain
Research published by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme has found that non-steroidal anti-inflammatory (NSAIDs) creams is as effective as tablets for the treatment of chronic knee pain in older people.
Neurocrine Biosciences Completes 'Petal Study' Treatment Phase For Endometriosis
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced that the elagolix 0603 Phase IIb trial (Petal Study) has completed the 6-month treatment phase. The last subject completed her Week 24 study visit in early June. This Phase IIb trial assesses the impact of elagolix treatment on bone mineral density (BMD) as the primary endpoint using Dual Energy X-ray Absorptiometry (DXA) scans to document any change from baseline.
Canadians Without Risk Factors Need Bone Density Measurements Only Once Every 5 Years According To Largest Ever Canadian Study On Osteoporosis
Dr David Goltzman and his team from the Research Institute of the McGill University Health Centre (RI MUHC) and McGill University - along with colleagues from across Canada - have issued new recommendations to public health authorities about how to best cope with osteoporosis, a bone disease which leads to increased risk of fracture, particularly in the elderly.
Adult Stem Cells Improve Fracture Healing
Adult stem cells improve healing of broken bones and could eventually serve as a new treatment for the 10 to 20 percent of fractures that fail to heal, according to a new study. The results were presented at The Endocrine Society's 90th Annual Meeting in San Francisco, by Froilan Granero-Molto, PhD, research associate of the University of North Carolina.
Boehringer Ingelheim Announces First Positive Health Technology Assessments For Novel Oral Anticoagulant Pradaxa reg; dabigatran Etexilate
The Scottish Medicines Consortium (SMC) has accepted Pradaxa (dabigatran etexilate) for routine use within the National Health Service (NHS) of Scotland for its currently licensed indication: the prevention of venous thromboembolic events in adults who have undergone total hip or knee replacement surgery.
Genta Announces Initial Clinical Trial Results For G4544, A Novel Potent Drug For Bone Disease
Genta Incorporated (OTC Bulletin Board: GNTA) announced the release of final results from the Company's Phase 1 clinical trial of G4544, a proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. Results showed that the drug was very well-tolerated, and that blood levels were achieved in a range that is known to be clinically bioactive.